Clinical Trial Validates Postbiotic Cultured Protein as a Viable Alternative to Whey

According to a press release from Superbrewed Food, a randomized crossover study presented at NUTRITION 2026 demonstrated that the company's Postbiotic Cultured Protein (SB1) produced an anabolic response and amino acid bioavailability statistically comparable to whey protein isolate in healthy adults. Conducted at Texas A&M University and published in Clinical Nutrition, the trial represents the first head-to-head intracellular comparison of a postbiotic protein against whey and pea isolates using stable isotope methodology, raising questions about the assumed hierarchy of protein quality based on dietary source alone.

A intracellular tracer, not a plasma proxy

The work, led by Nicolaas E.P. Deutz, MD, PhD, FASN, Director of the Center for Translational Research in Aging & Longevity at Texas A&M, employed a stable isotope pulse technique that simultaneously measures amino acid bioavailability and the intracellular anabolic response to a meal. Per Dr. Deutz, the method captures "how efficiently the body actually uses those amino acids inside the cell to build new protein," rather than relying on circulating plasma concentrations—a distinction with clinical implications for any protein source whose digestion kinetics deviate from the whey reference standard.

Trial outcomes

• Design: single-blind, randomized, placebo-controlled crossover; n=10 healthy adults (5 women, 5 men; mean age 31.4 ± 5.3 years; BMI 25.2 ± 4.0).
• Primary comparison: SB1 vs. whey protein isolate—anabolic response and amino acid bioavailability statistically comparable.
• Secondary comparison: SB1 vs. pea protein isolate—anabolic response and amino acid bioavailability equal to or exceeding pea.
• Mechanistic finding: lysine emerged as the limiting amino acid across all three sources, including whey, indicating that protein quality must be empirically measured rather than inferred from label claims or source category.

Verdict and what to track

Data, pending full peer review of the published Clinical Nutrition manuscript, suggest that fermentation-derived postbiotic proteins may achieve intracellular anabolic efficacy statistically indistinguishable from the dairy benchmark at a single acute dose. The trial is small (n=10) and short-term, however; replication in larger cohorts, older adults at risk of sarcopenia, and resistance-training contexts remains to be demonstrated. For formulators and clinicians evaluating alternatives to whey, the lysine-limiting finding across all three sources is the more durable takeaway: leucine-centric marketing narratives ignore that an isolated amino acid deficit will constrain the anabolic ceiling regardless of the protein matrix.

Across consumer categories, the same evidentiary standard is reshaping purchasing decisions—prospective buyers of new technology increasingly demand third-party performance data over manufacturer claims, a shift documented in independent reviews of EV models, charging infrastructure, and total cost of ownership. Nutrition research appears to be catching up.